OncoCyte Historical Income Statement
| OCX Stock | USD 2.44 0.09 3.56% |
Historical analysis of OncoCyte Corp income statement accounts such as Other Operating Expenses of 23.2 M can show how well OncoCyte Corp performed in making a profits. Evaluating OncoCyte Corp income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of OncoCyte Corp's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining OncoCyte Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether OncoCyte Corp is a good buy for the upcoming year.
OncoCyte |
About OncoCyte Income Statement Analysis
OncoCyte Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to OncoCyte Corp shareholders. The income statement also shows OncoCyte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
OncoCyte Corp Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of OncoCyte Corp. It is also known as OncoCyte Corp overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from OncoCyte Corp's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into OncoCyte Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OncoCyte Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.At this time, OncoCyte Corp's Selling General Administrative is fairly stable compared to the past year. Gross Profit is likely to rise to about 433.6 K in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.4 M in 2024.
OncoCyte Corp income statement Correlations
Click cells to compare fundamentals
OncoCyte Corp Account Relationship Matchups
High Positive Relationship
High Negative Relationship
OncoCyte Corp income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 344K | 394K | 4.2M | 5.2M | 1.7M | 1.4M | |
| Interest Expense | 299K | 252K | 209K | 77K | 52K | 49.4K | |
| Selling General Administrative | 13.3M | 16.8M | 22.3M | 21.9M | 10.7M | 11.2M | |
| Other Operating Expenses | 22.2M | 34.9M | 54.7M | 31.3M | 26.6M | 23.2M | |
| Operating Income | (22.2M) | (29.7M) | (46.9M) | (18.0M) | (25.1M) | (26.4M) | |
| Ebit | (22.0M) | (30.9M) | (52.7M) | (18.5M) | (24.8M) | (26.0M) | |
| Research Development | 6.8M | 9.8M | 13.6M | 7.3M | 9.3M | 7.8M | |
| Ebitda | (21.7M) | (30.5M) | (48.5M) | (13.3M) | (23.1M) | (24.3M) | |
| Total Operating Expenses | 22.2M | 33.1M | 47.1M | 30.3M | 25.6M | 22.1M | |
| Income Before Tax | (22.4M) | (31.2M) | (73.4M) | (18.6M) | (24.9M) | (26.1M) | |
| Net Income | (22.3M) | (29.9M) | (64.1M) | (73.4M) | (27.8M) | (29.2M) | |
| Total Revenue | 16K | 1.2M | 7.7M | 958K | 1.5M | 1.3M | |
| Gross Profit | (344K) | (639K) | 188K | (18K) | 413K | 433.7K | |
| Net Income From Continuing Ops | (22.4M) | (29.9M) | (64.1M) | (18.6M) | (20.9M) | (21.9M) | |
| Cost Of Revenue | 344K | 1.9M | 7.5M | 976K | 1.1M | 1.5M | |
| Total Other Income Expense Net | (187K) | (1.5M) | 854K | (615K) | 281K | 295.1K | |
| Net Income Applicable To Common Shares | (22.4M) | (29.9M) | (64.1M) | (73.4M) | (66.1M) | (62.8M) | |
| Income Tax Expense | (97K) | (1.3M) | (9.3M) | 54.8M | 2.9M | 5.1M | |
| Selling And Marketing Expenses | 2.2M | 6.5M | 11.2M | 1.1M | 2.8M | 3.6M | |
| Net Interest Income | 299K | (252K) | (209K) | (77K) | 96K | 100.8K | |
| Reconciled Depreciation | 351K | 1.9M | 4.2M | 5.2M | 2.6M | 2.4M | |
| Non Operating Income Net Other | (486K) | (1.2M) | 1.1M | (538K) | (618.7K) | (649.6K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.